Abstract:Background: Despite advances in our understanding of basic mechanisms driving post-surgical pain, treating incision-induced pain remains a major clinical challenge. Moreover, surgery has been implicated as a major cause of chronic pain conditions. Hence, more efficacious treatments are needed to inhibit incision-induced pain and prevent the transition to chronic pain following surgery. We reasoned that activators of AMP-activated protein kinase (AMPK) may represent a novel treatment avenue for the local treatment of incision-induced pain because AMPK activators inhibit ERK and mTOR signaling, two important pathways involved in the sensitization of peripheral nociceptors. Results: To test this hypothesis we used a potent and efficacious activator of AMPK, resveratrol. Our results demonstrate that resveratrol profoundly inhibits ERK and mTOR signaling in sensory neurons in a time- and concentration-dependent fashion and that these effects are mediated by AMPK activation and independent of sirtuin activity. Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo through a local mechanism of action. Using a model of incision-induced allodynia in mice, we further demonstrate that local injection of resveratrol around the surgical wound strongly attenuates incision-induced allodynia. Intraplantar IL-6 injection and plantar incision induces persistent nociceptive sensitization to PGE 2 injection into the affected paw after the resolution of allodynia to the initial stimulus. We further show that resveratrol treatment at the time of IL-6 injection or plantar incision completely blocks the development of persistent nociceptive sensitization consistent with the blockade of a transition to a chronic pain state by resveratrol treatment. Conclusions: These results highlight the importance of signaling to translation control in peripheral sensitization of nociceptors and provide further evidence for activation of AMPK as a novel treatment avenue for acute and chronic pain states.

Activation of Adenosine Monophosphate–activated Protein Kinase Suppresses Neuroinflammation and Ameliorates Bone Cancer Pain

AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation

Involvement of Adrenomedullin in Bone Cancer Pain in Rats

Activation of the Camp-Pka Signaling Pathway in Rat Dorsal Root Ganglion and Spinal Cord Contributes Toward Induction and Maintenance of Bone Cancer Pain.

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression

Resveratrol Reduces Morphine Tolerance by Inhibiting Microglial Activation Via AMPK Signalling.

Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models.

The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin

Sodium aescinate alleviates bone cancer pain in rats by suppressing microglial activation via p38 MAPK/c-Fos signaling

Impacts of anti-nerve growth factor antibody on pain-related behaviors and expressions of opioid receptor in spinal dorsal horn and dorsal root ganglia of rats with cancer-induced bone pain

[Express] Roles of TNF-α and IL-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1.

AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.

Extracellular Signal-Regulated Kinase Activation in Spinal Astrocytes and Microglia Contributes to Cancer-Induced Bone Pain in Rats

Resveratrol Engages AMPK to Attenuate ERK and mTOR Signaling in Sensory Neurons and Inhibits Incision-Induced Acute and Chronic Pain

Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization

Blockade of Spinal Dopamine D1/D2 Receptor Suppresses Activation of NMDA Receptor Through Gαq and Src Kinase to Attenuate Chronic Bone Cancer Pain

Metformin Attenuates Bone Cancer Pain by Reducing TRPV1 and ASIC3 Expression

CREB-regulated Transcription Coactivator 1 Enhances CREB-dependent Gene Expression in Spinal Cord to Maintain the Bone Cancer Pain in Mice.

B14 ameliorates bone cancer pain through downregulating spinal interleukin-1β via suppressing neuron JAK2/STAT3 pathway

Glycogen synthase kinase‐3β inhibition decreases inflammation and relieves cancer induced bone pain via reducing Drp1‐mediated mitochondrial damage